BioSpace News Archive

Rentschler Biopharma will establish their ATMP development and manufacturing capabilities at the Cell and Gene Therapy Catapult facility in Stevenage

One year ago , with the adoption of virtual care in Canada still lagging, the Virtual Care Task Force – a collaboration of the Canadian Medical Association, the Royal College of Physicians and Surgeons of Canada, and the College of Family Physicians of Canada – identified 19 recommendations to accelerate the implementation of virtual care.

Lucira Health, Inc., announced that U.S. physicians and healthcare providers can now order Lucira COVID-19 All-In-One Test Kits online from lucirahealth.com.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021.

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the BMO BioPharma Spotlight Series: Proteins – Degraders and Other Next Gen Technologies

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that the company management will participate in three upcoming virtual investor conferences.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company will host a conference call and live webcast on Thursday, February 25, 2021 at 8:00 a.m

Data Readout from Potentially Pivotal Phase 2/3 INAD Trial Expected 1H ‘01; Phase 2 ALS and Pivotal Phase 2/3 Friedreich’s Ataxia Trial Readouts Expected by Year-End

Recro Pharma, Inc. (“Recro”; NASD: REPH), a dedicated contract development and manufacturing organization (CDMO) solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the continued strengthening of its leadership through key appointments to its management team and board of directors

Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges (Yu, W et al.) , in the highly rated peer-reviewed journal, Annals of Oncology ( link ).